IPO Issue Details
Issue Price / Price Band₹114 per share (Fixed Price)
Face Value₹10 Per Share
Lot Size1,200 Shares per Lot
Total Issue Size61,78,800 shares (aggregating up to ₹70.44 Cr)
Issue TypeBookbuilding IPO
Sale Type / CategoryFresh Capital-cum-Offer for Sale
Exchange / PlatformBSE SME
IPO TypeSME
Subscription OpenTue, 11 Nov 2025
Subscription CloseThu, 13 Nov 2025
Anchor AllotmentMon, 10 Nov 2025
Basis of AllotmentFri, 14 Nov 2025
Initiation of RefundsMon, 17 Nov 2025
Credit of Shares to DematMon, 17 Nov 2025
Listing DateTue, 18 Nov 2025
UPI Mandate Deadline2025-11-13
Application & Investment Details
Retail — Min (2 Lots)₹2,73,600 — 2,400 shares
Retail — Max (13 Lots)₹1,778,400 (13 Lots)
HNI — Min (3 Lots)₹4,10,400 — 3,600 shares
EPS (Pre-IPO)₹7.29
EPS (Post-IPO)₹7.01
P/E Ratio (Pre-IPO)15.65x
P/E Ratio (Post-IPO)16.25x
Net Offer to Public58,69,200 shares (aggregating up to ₹66.91 Cr)
Reserved for Market Maker3,09,600 shares (aggregating up to ₹3.53 Cr)
Pre-IPO Promoter Holding1,77,66,200 shares
Post-IPO Promoter Holding2,34,05,000 shares
Fresh Issue Shares53,29,200 shares (aggregating up to ₹60.75 Cr)
Offer for Sale Shares5,40,000 shares of ₹10 (aggregating up to ₹6.16 Cr)
About Mahamaya Lifesciences Ltd.
Incorporated in 2002, Mahamaya Lifesciences Limited is engaged in manufacturing, registration and export of finest crop protection products and bioproducts for crop & soil health management and to help the farming community for more productivity.The company specializes in manufacturing pesticide formulations and supplying bulk products to Indian agrochemical companies and multinational corporations (MNCs).The company imports carefully researched molecules, registers them with the Central Insecticides Board, and markets them as technical and value-added formulations for domestic manufacturers and multinational corporations (MNCs).The company has invested in global product registrations, with active markets in countries like the Dominican Republic, Egypt, Ethiopia, Jordan, UAE, and Turkey, offering high-quality products and data support for registrations.Product Portfolio:Bulk Formulations Sales: Acetamiprid, SP Buprofezin, SC Emamectin benzoate, SG Imidacloprid, SC Paraquat Dichloride.Technical Sales: Acetamiprid Technical 99% Min, Atrazine Technical 95% Min, Imidacloprid Technical 95% Min, Emamectin Benzoate Technical 95% Min.Branded Sales (Major own branded products): MAYAMRIT GR, MAYAMRIT SL, MAYAGIBB, UCHIT EW 370Export Sales- Formulations: Wiper (Sulphur 80% WDG), Lancha (Pendimethalin 50% EC), Tolfen (Tolfenpyrad 15% EC), Typic (80% Sulphur WG).Competitive Strengths:Experienced management team consisting of experts.Capability to introduce vital products for Indian Agriculture.Development of export opportunities of products.Ability to develop brands.Cordial relationships with suppliers of raw materials.Core values focused on achieving sustainability through innovative approaches.
Objects of the Issue
Mahamaya Lifesciences Ltd. proposes to utilise the net proceeds from the Issue for the following objects:
1
1 Purchase of Equipment for existing Formulation plant
3.75
2
2 Funding capital expenditure towards setting up of a new technical manufacturing plant
29.42
3
3 Construction of Warehouse Building and Purchase of Machinery
2.53
4
4 Funding working capital requirement of our Company
18.00
5
5 General Corporate purposes
Shareholding & Lock-in
Pre-IPO Promoter Holding
1,77,66,200 shares
Post-IPO Promoter Holding
2,34,05,000 shares